Ivosidenib 250 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg
Reference Brands: Tibsovo (USA/EU)
Category: Oncology Cancer Care
Ivosidenib 250 mg film-coated tablets, an oral IDH1 inhibitor for IDH1-mutated acute myeloid leukaemia and cholangiocarcinoma. For hospital haematology and oncology pharmacies, importers and distributors.
Manufacture or export Ivosidenib? List it or send an offer →
Product Description:
Ivosidenib is an oral, selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The mutated enzyme makes an abnormal metabolite, 2-hydroxyglutarate, which blocks normal cell maturation; ivosidenib cuts its production and lets malignant cells differentiate again. It is supplied as 250 mg film-coated tablets. The usual dose is 500 mg once daily, taken as two tablets. It only works in tumours with an IDH1 mutation, which must be confirmed with a validated test before prescribing.
Approved uses include IDH1-mutated acute myeloid leukaemia, newly diagnosed in adults unfit for intensive chemotherapy, often with azacitidine, and in some markets relapsed or refractory disease. It is also used for previously treated, advanced cholangiocarcinoma with an IDH1 mutation, and in some markets for myelodysplastic syndromes. Differentiation syndrome is the key warning in leukaemia and needs prompt corticosteroids. ECGs are checked for QT prolongation. Strong CYP3A4 inhibitors need a dose reduction, inducers are avoided, and so are high-fat meals.
Sourcing notes. Ivosidenib is a recent targeted medicine, so ask how the offered product is registered in your market and whether it is the originator or a generic permitted under local patent rules. A CTD dossier is standard. Confirm the storage condition and ask for zone IVb stability data for tropical markets. Each lot needs a CoA, with a site GMP certificate and a CoPP on file. It is prescription-only and usually dispensed by hospital haematology or oncology pharmacies. Treatment depends on a companion diagnostic, so check which IDH1 test is approved locally. Specify pack size, quantity and remaining shelf life.
Ivosidenib — third party manufacturing & bulk supply
Ivosidenib 250 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Ivosidenib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ivosidenib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Ivosidenib →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Ivosidenib is used for the treatment of adult patients with IDH1-mutated acute myeloid leukemia and other IDH1-mutated malignancies, as determined by an FDA-approved diagnostic test.
Ivosidenib is a small-molecule synthetic compound designed to selectively inhibit the mutant IDH1 enzyme involved in abnormal cancer cell metabolism.
The trade name of ivosidenib is Tibsovo.
Ivosidenib (Tibsovo) is manufactured by Servier Pharmaceuticals.
The generic name is ivosidenib.
The brand name is Tibsovo.
Ivosidenib is manufactured in regulated pharmaceutical facilities operated by Servier Pharmaceuticals for the USA, EU, and UK markets.
Related Products
Crizotinib Capsules
Strength:
200mg, 250mg
Form: Capsules
Reference Brands: Xalkori (US/EU)
View DetailsOsimertinib Tablets
Strength:
40 mg, 80 mg
Form: Tablets
Reference Brands: Tagrisso (USA/EU)
View DetailsIxazomib Capsule
Strength:
2.3mg, 3mg, 4mg
Form: Capsules
Reference Brands: Ninlaro (US/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit